PALO ALTO, Calif., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today reported that it received a notice (the “Notice”) on November 21, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it was not in compliance with ...

Scilex management is determined to enhance its stockholders’ value and protect their stockholder rights, and is taking steps to combat manipulative and naked short selling practices in Scilex common stock.Scilex notified NASDAQ on October 28, 2024 that it has set a record date of November 7, 2024 for the dividend of Scilex preferred stock to Scilex’s stockholders and certain other securityholders of Scilex. Such record date may be changed by Scilex’s board of directors for any reason at any time prior to th ...

Scilex notified NASDAQ on October 28, 2024 that it has set a record date of November 7, 2024 (the "Record Date") for the dividend of Scilex preferred stock to Scilex's stockholders and certain other securityholders of Scilex. Based on independent market research conducted by Syneos Health Consulting ("Syneos"), with the substantial intent in utilization for SP-102 (SEMDEXA™), the product candidate held by Semnur Pharmaceuticals, Inc. ("Semnur") is estimated to have peak sales potential projected to be $3.6 ...

Sales Growth Estimates - ZTlido net sales for Q3 2024 estimated between $11.0 million to $13.0 million, representing growth of approximately 9% to 29% compared to the same period last year[3] - Total product net sales for Q3 2024 estimated between $12.0 million to $14.0 million, representing growth of approximately 19% to 39% compared to the same period last year[3] Financial Reporting - Preliminary unaudited financial results for Q3 2024 were issued in a press release on October 8, 2024[4]

ZTlido net sales for the quarter ended September 30, 2024 were in the range of $11.0 million to $13.0 million, compared to $10.1 million for the same period last year, representing growth in the range of approximately 9% to 29%. Total product net sales for the quarter ended September 30, 2024 were in the range of $12.0 million to $14.0 million, compared to $10.1 million for the same period last year, representing growth in the range of approximately 19% to 39%. PALO ALTO, Calif., Oct. 08, 2024 (GLOBE NEWSWI ...

PALO ALTO, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, "Scilex" or the "Company"), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced the closing of its previously announced registered direct offering of new tranche B senior secured convertible notes (the "Notes") in the aggregate principal amount of $50 million and warrants to purcha ...

Affiliates of Murchinson, 3i LP, and existing senior debt holder, Oramed Pharmaceuticals, Inc. ("Oramed"), are expected to participate in the $50 million convertible note offering, which is expected to close on or about October 7, 2024. The offering involves a refinancing and restructuring of existing debt and is expected to position Scilex for sustainable, long-term growth, as part of its multi-year plan to transform into a potential global and leading non-opioid pain management company. Scilex will receiv ...

PALO ALTO, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, "Scilex" or the "Company"), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced oral, poster presentations, and symposia on ZTlido (lidocaine topical system) at the 2024 Annual PAINWeek conference in Las Vegas, NV on September 3-5, 2024. Key highlights of the ZTlido (lidocaine topi ...

FDA Final Approval to Precision Dosing for GLOPERBA® Label. We believe GLOPERBA® is the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. Gout is a painful arthritic disorder affecting an estimated 9.2 million people in the United States1. As gout cases increase every year, treatment requirements increase. According to data gathered by Evaluate Pharma, the gout treatment market is projected to reach $2.0 billion in the U.S ...

Core Insights - Scilex Holding Company announced that the U.S. Patent and Trademark Office will issue a new patent related to the treatment of acute pain, further strengthening its intellectual property for ELYXYB®, an FDA-approved oral solution for acute migraine treatment, expected in late 2024 [1][2] Company Overview - Scilex is focused on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain, targeting high unmet needs and large market opportunities [4][6] - The company’s commercial products include ZTlido®, ELYXYB®, and Gloperba®, with ELYXYB® being the only FDA-approved ready-to-use oral solution for acute migraine treatment [4][5] Market Potential - The U.S. oral migraine drug market was estimated at $1.8 billion in 2022, while the total acute pain market was approximately $3 billion in 2021 [1][4] - There are about 100 million cases of acute pain in the U.S., indicating a significant market opportunity for non-opioid therapies [1][4] Product Efficacy - ELYXYB® has shown rapid pain relief in clinical studies, with patients experiencing relief in as little as 15 minutes and significant pain relief compared to placebo within 45 minutes in about 50% of patients [2][4] - The product is positioned as a first-line non-opioid therapeutic alternative to opioids and acetaminophen, which are associated with risks such as acute liver failure [1][2] Future Developments - The new patent will enable Scilex to file future applications for acute pain treatments, enhancing its product portfolio and market presence [2][4]